United States · Markets & Finance · Quartz

FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance

Published by Quartz · United States 1 h ago

The Molecular and Clinical Genetics Panel is weighing the Galleri test's clinical evidence today; Medicare coverage could follow FDA approval

Read the full article on Quartz Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (qz.com)

Also worth reading

NY Fed's Williams sees one more rate hike this year, none in 2027

Bitcoin Whale That Sat Through Every Crash Since 2020 Just Moved $377M

Here’s what happened in crypto today

Apple releases HomeView smart home hub with screen as showcase for Siri AI

Business Insider

It pays to switch jobs again, but not everyone has that luxury

Police Identify 42-Year Old Man Killed at Six Flags Over Georgia